Scholarlink

<p>Rett syndrome (RTT) is a rare, genetic, neurodevelopmental disorder that predominantly affects girls. Clinical presentation is defined by regression of acquired motor and communication skills followed by stabilisation or recovery. Other clinical features can include decelerated head growth, breathing difficulties and seizures. Clinicians must therefore balance treatment of multiple comorbidities throughout the management of RTT. Trofinetide is the first drug approved specifically for treatment of neurological symptoms of RTT. While the number of RTT therapy trials has expanded in recent years, positive results have been limited. Additional preclinical and clinical investigations are ongoing.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Consider trofinetide for symptom management in Rett syndrome, with new therapies requiring further study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月10日

查看全文
  • Thomas B. Burgess,
  • Sheridan M. Hoy

摘要

Rett syndrome (RTT) is a rare, genetic, neurodevelopmental disorder that predominantly affects girls. Clinical presentation is defined by regression of acquired motor and communication skills followed by stabilisation or recovery. Other clinical features can include decelerated head growth, breathing difficulties and seizures. Clinicians must therefore balance treatment of multiple comorbidities throughout the management of RTT. Trofinetide is the first drug approved specifically for treatment of neurological symptoms of RTT. While the number of RTT therapy trials has expanded in recent years, positive results have been limited. Additional preclinical and clinical investigations are ongoing.